We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead (GILD) to Report Q4 Earnings: Is a Beat in the Cards?
Read MoreHide Full Article
Biotech major Gilead Sciences Inc. (GILD - Free Report) is slated to report fourth-quarter 2021 results on Feb 1, after market close.
The company has an excellent track record, with earnings beating estimates in all of the last four quarters, the average beat being 15.7%. In the last reported quarter, the company beat expectations by 54.07%.
Our proven model predicts an earnings beat for Gilead this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP for Gilead is +2.03%, as the Zacks Consensus Estimate is pegged at $1.50 and the Most Accurate Estimate is pegged at $1.53.
Zacks Rank: The company currently carries a Zacks Rank #3.
Factors at Play
Gilead did not provide any guidance for the fourth quarter. It upped its product sales outlook for 2021 concurrent with the third-quarter results suggesting an increase in sales in the fourth quarter.
A decline in HIV franchise sales due to the loss of exclusivity of Truvada and Atripla adversely impacted the top line in the third quarter. Sales from this franchise came in at $4.2 billion in the third quarter. The trend is likely to have continued in the fourth quarter as well. Flagship HIV therapy, Biktarvy, saw continued growth and gains in market share, despite the ongoing impact of the pandemic in all three quarters. The trend is expected to have continued in the final quarter. Strong growth in Biktarvy sales might have offset the overall decline in sales in the quarter.
Descovy sales decreased in the previous quarter due to lower net price. A similar trend has most likely prevailed in the to-be-reported quarter. The Zacks Consensus Estimate for sales of Biktarvy and Descovy is pegged at $2.4 billion and $435 million, respectively.
Like the third quarter, HCV sales are likely to have decreased due to fewer patient starts outside the United States. A surge in COVID-19 cases due to the Omicron variant both in the United States and Europe has most likely resulted in lower patient starts this quarter as well.
Veklury (remdesivir) sales, an antiviral treatment for COVID-19, contributed $1.9 billion to the top line in the third quarter. Given the surge in sales of antibody treatments, sales of Veklury are likely to have declined or remained stable sequentially in the fourth quarter. The Zacks Consensus Estimate for Veklury sales is pegged at $755 million.
Cell Therapy product sales, which include Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel), came in at $222 million in the previous quarter. Sales might have experienced a sequential increase, driven by label expansions. The Zacks Consensus Estimate for Yescarta sales stands at $194 million.
Trodelvy (for breast cancer) sales came in $101 million in the third quarter, reflecting increased use for the second-line treatment of metastatic triple-negative breast cancer (TNBC) and metastatic urothelial cancer in the United States. The drug was added following the acquisition of Immunomedics by Gilead in 2020. Sales might have registered a sequential increase as demand is normalizing.
Operating expenses might have increased due to higher investments in the oncology program.
Other Pipeline & Regulatory Updates
Apart from the regular top and bottom-line numbers, we expect investors to focus on key pipeline updates.
The FDA has approved the label expansion of antiviral treatment Veklury for COVID-19. The regulatory body has granted expedited approval to a supplemental new drug application (sNDA) for Veklury for the treatment of non-hospitalized adult and adolescent patients who are at high risk of progression to severe COVID-19, including hospitalization or death. The FDA has also expanded the pediatric Emergency Use Authorization (EUA) of Veklury to include non-hospitalized pediatric patients younger than 12 years of age who are at high risk of disease progression. National Institutes of Health Treatment Guidelines for COVID-19 has additionally recommended Veklury for treatment in non-hospitalized settings. This should propel the guidance for the drug.
The European Commission has granted marketing authorization to Trodelvy as a monotherapy indicated for the treatment of adult patients with unresectable or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for advanced disease. Approval in additional geographies should boost the growth potential of the drug.
Share Price Performance
Gilead’s stock has gained 2.5% in the year so far against the industry's decline of 39.3%.
Image Source: Zacks Investment Research
Other Stocks to Consider
Here are some other drug/biotech stocks you may want to consider, as our model shows that these too have the right combination of elements to post an earnings beat this season.
Pfizer boasts of a good track record, having topped earnings estimates in three of the last four quarters. Pfizer pulled off a four-quarter earnings surprise of 10.85%, on average.
Amgen (AMGN - Free Report) has an Earnings ESP of +1.49% and a Zacks Rank #3.
Amgen has a decent track record and topped earnings estimates in three of the last four quarters. Amgen delivered a four-quarter earnings surprise of 5.65%, on average.
AbbVie (ABBV - Free Report) has an Earnings ESP of +0.26% and a Zacks Rank #3.
AbbVie has an excellent record and topped earnings estimates in the past four quarters. AbbVie pulled off a four-quarter earnings surprise of 3.02%, on average.
Image: Bigstock
Gilead (GILD) to Report Q4 Earnings: Is a Beat in the Cards?
Biotech major Gilead Sciences Inc. (GILD - Free Report) is slated to report fourth-quarter 2021 results on Feb 1, after market close.
The company has an excellent track record, with earnings beating estimates in all of the last four quarters, the average beat being 15.7%. In the last reported quarter, the company beat expectations by 54.07%.
Gilead Sciences, Inc. Price and EPS Surprise
Gilead Sciences, Inc. price-eps-surprise | Gilead Sciences, Inc. Quote
What Our Model Predicts
Our proven model predicts an earnings beat for Gilead this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP for Gilead is +2.03%, as the Zacks Consensus Estimate is pegged at $1.50 and the Most Accurate Estimate is pegged at $1.53.
Zacks Rank: The company currently carries a Zacks Rank #3.
Factors at Play
Gilead did not provide any guidance for the fourth quarter. It upped its product sales outlook for 2021 concurrent with the third-quarter results suggesting an increase in sales in the fourth quarter.
A decline in HIV franchise sales due to the loss of exclusivity of Truvada and Atripla adversely impacted the top line in the third quarter. Sales from this franchise came in at $4.2 billion in the third quarter. The trend is likely to have continued in the fourth quarter as well. Flagship HIV therapy, Biktarvy, saw continued growth and gains in market share, despite the ongoing impact of the pandemic in all three quarters. The trend is expected to have continued in the final quarter. Strong growth in Biktarvy sales might have offset the overall decline in sales in the quarter.
Descovy sales decreased in the previous quarter due to lower net price. A similar trend has most likely prevailed in the to-be-reported quarter. The Zacks Consensus Estimate for sales of Biktarvy and Descovy is pegged at $2.4 billion and $435 million, respectively.
Like the third quarter, HCV sales are likely to have decreased due to fewer patient starts outside the United States. A surge in COVID-19 cases due to the Omicron variant both in the United States and Europe has most likely resulted in lower patient starts this quarter as well.
Veklury (remdesivir) sales, an antiviral treatment for COVID-19, contributed $1.9 billion to the top line in the third quarter. Given the surge in sales of antibody treatments, sales of Veklury are likely to have declined or remained stable sequentially in the fourth quarter. The Zacks Consensus Estimate for Veklury sales is pegged at $755 million.
Cell Therapy product sales, which include Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel), came in at $222 million in the previous quarter. Sales might have experienced a sequential increase, driven by label expansions. The Zacks Consensus Estimate for Yescarta sales stands at $194 million.
Trodelvy (for breast cancer) sales came in $101 million in the third quarter, reflecting increased use for the second-line treatment of metastatic triple-negative breast cancer (TNBC) and metastatic urothelial cancer in the United States. The drug was added following the acquisition of Immunomedics by Gilead in 2020. Sales might have registered a sequential increase as demand is normalizing.
Operating expenses might have increased due to higher investments in the oncology program.
Other Pipeline & Regulatory Updates
Apart from the regular top and bottom-line numbers, we expect investors to focus on key pipeline updates.
The FDA has approved the label expansion of antiviral treatment Veklury for COVID-19. The regulatory body has granted expedited approval to a supplemental new drug application (sNDA) for Veklury for the treatment of non-hospitalized adult and adolescent patients who are at high risk of progression to severe COVID-19, including hospitalization or death. The FDA has also expanded the pediatric Emergency Use Authorization (EUA) of Veklury to include non-hospitalized pediatric patients younger than 12 years of age who are at high risk of disease progression. National Institutes of Health Treatment Guidelines for COVID-19 has additionally recommended Veklury for treatment in non-hospitalized settings. This should propel the guidance for the drug.
The European Commission has granted marketing authorization to Trodelvy as a monotherapy indicated for the treatment of adult patients with unresectable or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for advanced disease. Approval in additional geographies should boost the growth potential of the drug.
Share Price Performance
Gilead’s stock has gained 2.5% in the year so far against the industry's decline of 39.3%.
Other Stocks to Consider
Here are some other drug/biotech stocks you may want to consider, as our model shows that these too have the right combination of elements to post an earnings beat this season.
Pfizer (PFE - Free Report) has an Earnings ESP of +3.18% and a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Pfizer boasts of a good track record, having topped earnings estimates in three of the last four quarters. Pfizer pulled off a four-quarter earnings surprise of 10.85%, on average.
Amgen (AMGN - Free Report) has an Earnings ESP of +1.49% and a Zacks Rank #3.
Amgen has a decent track record and topped earnings estimates in three of the last four quarters. Amgen delivered a four-quarter earnings surprise of 5.65%, on average.
AbbVie (ABBV - Free Report) has an Earnings ESP of +0.26% and a Zacks Rank #3.
AbbVie has an excellent record and topped earnings estimates in the past four quarters. AbbVie pulled off a four-quarter earnings surprise of 3.02%, on average.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.